Regression of carotid atherosclerosis in high‐risk individuals with proprotein convertase subtilisin/kexin type 9 inhibitors

Documenti analoghi

• Statins, but not proprotein convertase subtilisin‐kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low‐density lipoprotein receptor upregulation
  di: Lunbo Tan, et al.
  Pubblicazione: (2024)
• Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia
  di: Hongyan Jiang, et al.
  Pubblicazione: (2024)
• Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9
  di: Alexander M. Cao Zhang, et al.
  Pubblicazione: (2024)
• Dapagliflozin modulates hepatic lipid metabolism through the proprotein convertase subtilisin/kexin type 9/low density lipoprotein receptor pathway
  di: Fengyuan Lu, et al.
  Pubblicazione: (2025)
• ASGR1 inhibitors, inflammation, and heart failure: A Mendelian randomization analysis
  di: Xingsheng Ye, et al.
  Pubblicazione: (2025)